Breast Cancer. Side Effects of Medical Cancer Therapy: Prevention and Treatment. Ed. Mario A. Dicato. Chapter 2: P29-117; Springer 2013, XIII.

Auteurs : Aftimos P, Gombos A, Pugliano L, Awada A, Piccart-Gebhart M
Année : 2013
Journal : Book
Volume : chapter2
Pages : P29-117

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.

Auteurs : Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Dixon JM, Piccart-Gebhart M, Sotiriou C
Année : 2013
Journal : PLoS One
Volume : 8(1)
Pages : e53292

Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.

Auteurs : Saghatchian M, Mook S, Pruneri G, Viale G, Glas AM, Guerin S, Cardoso F, Piccart-Gebhart M, Tursz T, Delaloge S, van t Veer L
Année : 2013
Journal : Breast
Volume : 22(5)
Pages : 682-90

Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2.

Auteurs : Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart-Gebhart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI
Année : 2013
Journal : J. Natl. Cancer Inst.
Volume : 105(9)
Pages : 654-63

Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.

Auteurs : Oakman C, Francis PA, Crown J, Quinaux E, Buyse M, de Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Jakesz R, Thürlimann B, Gutiérrez J, Harvey V, Punzalan L, Dell orto P, Larsimont D, Steinberg I, Gelber Rd, Piccart-Gebhart M, Viale G, Di Leo A
Année : 2013
Journal : Ann Oncol
Volume : 24(5)
Pages : 1203-11

Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience.

Auteurs : Metzger-Filho O, de Azambuja E, Bradbury I, Saini KS, Bines J, Simon SD, Dooren VV, Aktan G, Pritchard KI, Wolff AC, Smith I, Jackisch C, Lang I, Untch M, Boyle F, Xu B, Baselga J, Perez EA, Piccart-Gebhart M
Année : 2013
Journal : Oncologist
Volume : 18(2)
Pages : 134-40

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98.

Auteurs : Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart-Gebhart M, Sotiriou C
Année : 2013
Journal : J. Clin. Oncol.
Volume : 31(7)
Pages : 860-7

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

Auteurs : Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez RI, Müller V, Dodwell D, Gelber Rd, Piccart-Gebhart M, Cameron D
Année : 2013
Journal : Lancet Oncol
Volume : 14(3)
Pages : 244-8

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. (published online 11/2012)

Auteurs : Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabières C, Janni W, Messina C, Paoletti C, Müller V, Hayes DF, Piccart-Gebhart M, Pierga JY
Année : 2013
Journal : Cancer Metastasis Rev
Volume : 32(1-2
Pages : 179-88

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.(epub nov 2013)

Auteurs : Awada A, Dumez H, Hendlisz A, Wolter P, Besse-Hammer T, Uttenreuther-Fischer M, Stopfer P, Fleischer F, Piccart-Gebhart M, Schöffski P
Année : 2013
Journal : Invest New Drugs
Volume : 31(3)
Pages : 734-41

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.

Auteurs : Goss PE, Smith IE, + collaborators (among others :, Piccart-Gebhart M, Finkelstein DM
Année : 2013
Journal : Lancet Oncol
Volume : 14(1)
Pages : 88-96

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.

Auteurs : Kerklaan BM, Diéras V, Le Tourneau C, Mergui-Roelvink M, Huitema AD, Rosing H, Beijnen JH, Marreaud S, Govaerts AS, Piccart-Gebhart M, Schellens JH, Awada A
Année : 2013
Journal : Cancer Chemother Pharmacol
Volume : 71(1)
Pages : 53-62

Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.

Auteurs : Azim HA, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, De Mattos-Arruda L, Pistilli B, Pinto A, Jensen MB, Cordoba O, de Azambuja E, Goldhirsch A, Piccart-Gebhart M, Peccatori FA
Année : 2013
Journal : J. Clin. Oncol.
Volume : 31(1)
Pages : 73-9

Pertuzumab: new hope for patients with HER2-positive breast cancer.

Auteurs : Capelan M, Pugliano L, de Azambuja E, Bozovic I, Saini KS, Sotiriou C, Loi S, Piccart-Gebhart M
Année : 2013
Journal : Ann Oncol
Volume : 24(2)
Pages : 273-82

Genomic grade adds prognostic value in invasive lobular carcinoma.

Auteurs : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Sandy H, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Année : 2013
Journal : Ann Oncol
Volume : 24(2)
Pages : 377-84

HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab.

Auteurs : Zabaglo L, Stoss O, Rüschoff J, Zielinski D, Salter J, Arfi M, Bradbury I, Dafni U, Piccart-Gebhart M, Procter M, Dowsett M
Année : 2013
Journal : Ann Oncol
Volume : 24(11)
Pages : 2761-6

Autoimmune haemolytic anaemia in a patient treated with capecitabine.

Auteurs : Sideris S, Loizidou A, Georgala A, Lebrun F, Gil T, Awada A, Piccart-Gebhart M, Cardoso F
Année : 2013
Journal : Acta Clin Belg
Volume : 68(2)
Pages : 135-7

Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer.

Auteurs : Metzger-Filho O, Catteau A, Michiels S, Buyse M, Ignatiadis M, Saini KS, de Azambuja E, Fasolo V, Naji S, Canon JL, Delrée P, Coibion M, Cusumano P, Jossa V, Kains JP, Larsimont D, Richard V, Faverly D, Cornez N, Vuylsteke P, Vanderschueren B, Peyro-Saint-Paul H, Piccart-Gebhart M, Sotiriou C
Année : 2013
Journal : PLoS One
Volume : 8(8)
Pages : e66848

How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer.

Auteurs : Pinto AC, de Azambuja E, Piccart-Gebhart M
Année : 2013
Journal : Breast Care (Basel)
Volume : 8(4)
Pages : 264-269

Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

Auteurs : Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M
Année : 2013
Journal : Breast
Volume : 22 Suppl 2
Pages : S152-5